Literature DB >> 2534005

Immune response of lambs to experimental infection with Orf virus.

D L Yirrell1, H W Reid, M Norval, S E Howie.   

Abstract

A group of six specific pathogen free (SPF) lambs were infected epidermally with Orf virus. Seven weeks later they were reinfected. For a period of 4 weeks after each inoculation they were observed clinically and blood was collected for analysis of virus specific antibody measured by ELISA and peripheral blood lymphocyte (PBL) proliferative response to various viral antigens. After the primary infection all animals showed clinical signs of Orf, namely vesicle formation which became pustular followed by scabbing; this steadily became heavier prior to shedding and the resolution of the infection by about 4 weeks. The severity of infection varied within the group. Little lymphoproliferative activity was recorded during the primary infection, although five/six test animals had positive lymphoproliferative responses to an sodium dodecyl sulphate (SDS) solubilised scab purified Orf virus preparation at some point between days 7 and 14 after inoculation. All animals seroconverted to Orf virus, lymphoproliferative activity always preceding specific antibody detection. Resolution of the secondary infection was very rapid. Vesicles were visible by day 2 after inoculation which became pustular followed by scab formation and resolution in the majority of animals by day 8. All animals showed a significant (greater than four-fold) rise in specific antibody titre following secondary inoculation. The proliferative activity of PBL's was much greater than that recorded for the primary infection although the magnitude of this response varied greatly between individuals.

Entities:  

Mesh:

Substances:

Year:  1989        PMID: 2534005     DOI: 10.1016/0165-2427(89)90168-2

Source DB:  PubMed          Journal:  Vet Immunol Immunopathol        ISSN: 0165-2427            Impact factor:   2.046


  7 in total

1.  Cyclosporin A abrogates the acquired immunity to cutaneous reinfection with the parapoxvirus orf virus.

Authors:  D M Haig; C J McInnes; G Hutchison; H F Seow; H W Reid
Journal:  Immunology       Date:  1996-12       Impact factor: 7.397

2.  Antiviral activity of HPMPC (cidofovir) against orf virus infected lambs.

Authors:  A Scagliarini; C J McInnes; L Gallina; F Dal Pozzo; L Scagliarini; R Snoeck; S Prosperi; J Sales; J A Gilray; P F Nettleton
Journal:  Antiviral Res       Date:  2006-10-11       Impact factor: 5.970

3.  A novel inhibitor of the NF-{kappa}B signaling pathway encoded by the parapoxvirus orf virus.

Authors:  D G Diel; G Delhon; S Luo; E F Flores; D L Rock
Journal:  J Virol       Date:  2010-02-10       Impact factor: 5.103

4.  The restricted IgG1 antibody response to maedi visna virus is seen following infection but not following immunization with recombinant gag protein.

Authors:  P Bird; H T Reyburn; B A Blacklaws; D Allen; P Nettleton; D L Yirrell; N Watt; D Sargan; I McConnell
Journal:  Clin Exp Immunol       Date:  1995-11       Impact factor: 4.330

5.  Genomic comparison of an avirulent strain of Orf virus with that of a virulent wild type isolate reveals that the Orf virus G2L gene is non-essential for replication.

Authors:  C J McInnes; A R Wood; P E Nettleton; J A Gilray
Journal:  Virus Genes       Date:  2001-03       Impact factor: 2.198

6.  The whole genomic analysis of orf virus strain HN3/12 isolated from Henan province, central China.

Authors:  Huiqin Chen; Wei Li; Zhenzhan Kuang; Daxiang Chen; Xiaoqing Liao; Ming Li; Shuhong Luo; Wenbo Hao
Journal:  BMC Vet Res       Date:  2017-08-18       Impact factor: 2.741

Review 7.  Therapeutic immunomodulation using a virus--the potential of inactivated orf virus.

Authors:  O Weber; A A Mercer; A Friebe; P Knolle; H-D Volk
Journal:  Eur J Clin Microbiol Infect Dis       Date:  2012-11-22       Impact factor: 5.103

  7 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.